Our Mission
To provide genome-wide, high-quality proteins and antibodies built upon our proprietary cDNA clone collections through innovation and dedicated customer engagement, one target at a time.
Our Vision
Be the premier source for genomic & proteomic tools to accelerate scientific breakthroughs and novel diagnostics.
Our Purpose
Provide efficient, innovative, and comprehensive solutions for life science researchers, one target at a time.
Our History
1996
OriGene
In 1996, OriGene Technologies was founded as a research tool company that generated a large commercial collection of full-length human cDNAs with a mission to be “Your Gene Company,” supplying you with all tools for gene-based research. Today, we have stayed true to our mission, continuing to develop high-quality, innovative tools to empower researchers.
2008
TrueORF® Gold Collection
With over 25 years of experience, OriGene has accelerated gene function discovery with over 1 million cDNA clones. Our collection has been recognized for its broad coverage and, more importantly, its high quality. Producing in-stock expression-validated clones are ready for transfection.
2009
MVPro Recombinant Protein
Our R&D team has many years of experience in recombinant protein production and development. Over the years, our team has generated more than 10,000 recombinant proteins covering most hot research areas such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, and cytokines
2010
Introducing TrueMAB®
OriGene developed mouse monoclonal antibodies against full-length human protein as immunogens. These antibodies provide higher sensitivity and specificity compared to peptide -derived antibodies. TrueMAB’s are great tools for immunoassays that are sensitive to protein conformations, such as immunofluorescence, Immunoprecipitation and immunohistochemistry.
2011
17K Protein Chip
With a large collection of overexpression antigen standard, OriGene developed a high-density protein microarray chip for antibody evaluation at the proteome-wide level. This chip is spotted with over 17,000 overexpression proteins in duplicate on a single nitrocellulose coated glass slide, as well as various positive & negative controls
2012
Introducing UltraMAB
OriGene developed a high-density protein microarray for antibody specificity testing with the purpose of solving antibody non-specificity and cross-reactivity issues for diagnostic assays. We have established a library of 279 targets, which are extensively validated for specificity.
2013
Acquired SDIX
For over 30 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers worldwide to meet high-performance diagnostic and commercialization objectives. All sites are ISO 13485:2016 certified.
2014
CRISPR
To revolutionize the genome engineering technology, OriGene provides reagents to support a broad range of CRISPR/Cas9 gene editing application, from CRISPR vectors to gene knockout kits.
2015
Acquired ACRIS
Expanding our horizons to serve the scientific community better, OriGene partnered with ACRIS to increase it’s antibody portfolio. This acquisition sets the stage to serve our European customers with faster and better service and bring acris products to the global customer base.
2016
Introducing TrueRAB® Antibodies
To address the reproducibility crisis in the antibody market, we introduced TrueRAB. Recombinant antibodies that give consistent and reproducible results.
2021
CytoSections™
CytoSections are FFPE sections of transiently transfected cDNA-specific gene targets over-expressed in mammalian cells. They are reference slides used as positive and negative controls for IHC, ICC, and ISH.
